AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05194475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermogenic Ready-to-drink Beverage
Description: Thermogenic ready-to-drink beverage, which will be ingested by the participant.
Study NCT05194475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ready-to-drink Beverage
Description: Placebo ready-to-drink beverage, which will be ingested by the participant.
Study NCT06002646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
Study NCT06002646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite Solution
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
Study NCT06002646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.
Study NCT06002646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
Study NCT06226298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiaxi postural hammock
Description: Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
Study NCT06226298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga mat
Description: Lie in the Yoga mat for 10 minutes for 5 days.
Study NCT05413122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Counselling
Description: Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
Study NCT05413122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Counselling
Description: Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
Study NCT05387694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombotic risk assessment
Description: Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
Study NCT06474650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet
Description: Single-dose of 30 mg of LPM3770164 sustained release tablet
Study NCT06098716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Regulation
Description: How to plan for Family PA
Study NCT06098716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity & Family functioning
Description: Increasing self-identity to increase parental support of child PA \& family functioning
Study NCT05825651 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: This is an observational study without any intervention.
Study NCT06444828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative
Description: Non-operative treatment versus operative treatment (surgery)
Study NCT06246149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Tebentafusp will be administered weekly i.v.
Study NCT05606770 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Exercise
Description: Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
Study NCT05606770 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Physical Activity
Description: The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
Study NCT05281900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: Shoulder impingement and instability tests and shoulder normal range of motion measurement.
Study NCT06254755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical thrombectomy
Description: mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
Study NCT05281900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC measurements
Description: For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
Study NCT05281900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank
Study NCT05456633 — intervention group
Intervention type: DEVICE
Intervention: Capri Cervical Static
Description: When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
Study NCT05456633 — intervention group
Intervention type: OTHER
Intervention: CAPRI Static Expandable
Description: When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
Study NCT05456633 — intervention group
Intervention type: DEVICE
Intervention: Capri Thoracolumbar
Description: Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
Study NCT05821075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 60mg tablet once daily for 5 days then tapering dose
Study NCT05821075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: intramuscular Cerebrolysin 10 mg daily for 3 weeks
Study NCT06396013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment
Description: Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use.
Study NCT06396013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use.
Study NCT05816759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study NCT05816759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D744, D150
Description: QD, PO
Study NCT05172830 — intervention group
Intervention type: DEVICE
Intervention: Ovation Alto™ Abdominal Stent Graft System
Description: Single occurrence permanent implantation of AAA device
Study NCT04341558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family supplemented patient monitoring
Description: Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
Study NCT06254755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
Study NCT05828225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells injection
Description: CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
Study NCT06247670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-CPS-001
Description: CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
Study NCT06247670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is 0.9% normal saline solution and will be administered subcutaneously.
Study NCT05706987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: continuous lidocaine infusion perioperatively
Study NCT05706987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline
Study NCT04982627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI Chatbot
Description: The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
Study NCT04982627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OUD Education & Treatment Resources
Description: The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
Study NCT04938713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML
Description: Intravenous Ketalar® 0,30 mg/kg in 1 hour.
Study NCT04938713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine 50 MG/ML
Description: Intravenous Ketalar® 0,30 mg/kg in 1 hour.
Study NCT04938713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 25 MG/ML
Description: Intravenous Vesierra® 0,15mg/kg in 1 hour.
Study NCT04938713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esketamine 25 MG/ML
Description: Intravenous Vesierra® 0,15mg/kg in 1 hour.
Study NCT05469022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant lazertinib
Description: Lazertinib 240mg p.o once daily.
Study NCT06080165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and > 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
Study NCT06080165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT05956522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Empagliflozin And Linagliptin Tablets
Description: specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
Study NCT05956522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Empagliflozin And Linagliptin tablets
Description: specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
Study NCT04736732 — intervention group
Intervention type: OTHER
Intervention: Medical follow-up
Description: Patients will be followed for medical evaluation and for biobanking of data and biological samples.
Study NCT06371066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: the experimental group was educated by video
Study NCT06371066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: the control group was educated by traditional formal training
Study NCT05584085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-DE
Description: Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
Study NCT05584085 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ACT-DE
Description: Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
Study NCT06476431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task
Description: The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.
Study NCT06476431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non dual task
Description: No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
Study NCT05691621 — intervention group
Intervention type: DRUG
Intervention: Standard Reagents, Whole Blood
Description: All patients receive standard treatment, only their blood and urine samples are needed
Study NCT06306768 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Activity Monitoring
Description: Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
Study NCT04833400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICRS
Description: Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
Study NCT04833400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAET
Description: Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
Study NCT06093971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: Remimazolam is administered for anesthesia induction.
Study NCT06093971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered for anesthesia induction.
Study NCT05398705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cepharanthine
Description: Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
Study NCT05398705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc.
Study NCT05398705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cepharanthine
Description: High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc.
Study NCT05808816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Crispatus M247
Description: Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
Study NCT05856578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloid Tablet
Description: Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
Study NCT05856578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Canagliflozin 100mg po qd
Study NCT04761159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.
Study NCT05184621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eyesing Redlight Instrument
Description: Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.